TTR and plasma cell myeloma: Their medical history was remarkable for longstanding/poorly controlled HTN with chronic kidney disease/end-stage renal kidney disease (4/10); longstanding/poorly controlled HTN, end-stage renal kidney disease and TTR mutation (1/10); longstanding/poorly controlled HTN with multiple myeloma (1/10); longstanding HTN with CAD (1/10); short history of HTN with multiple myeloma (1/10); or short history of HTN with CAD (2/10).